ImmuPharma Sponsors the 2014 European Lupus Conference

11th April 2014 - 10:53 am

ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to confirm that it is sponsoring the forthcoming European Lupus Conference which takes place in Athens, Greece from April 23 – 26, 2014.

The “European Lupus Meetings” is a major forum for all people interested in the disease: with approximately 800 physicians of various disciplines (internal medicine, rheumatology, nephrology, dermatology, obstetrics and gynecology, neurology), health professionals, regulatory agencies, pharmaceutical industry and patient representatives.
ImmuPharma recently had confirmation from Dr. Sylviane Muller, Research Director at CNRS, Strasbourg, France and the key inventor of Lupuzor, that she has been invited to present at the conference.  Her talk is planned  in the Basic and Translational Symposium (15-16.30pm CET) on Thursday April 24.  The title of the session is called “A novel way of immunomodulation in lupus”.  Her presentation will focus partly on the on the highly competitive and efficacious mode of mechanism of LupuzorTM, ImmuPharma’s potential blockbuster drug for Lupus, a chronic autoimmune disease. LupuzorTM has received Special Protocol Assessment and Fast Track Designation from the FDA for a Phase III trial.
Also in attendance at the conference will be two of ImmuPharma’s eminent ‘Scientific Advisory Board’, Dr. Daniel J. Wallace, Associate Director, Rheumatology Fellowship Program, Cedars-Sinai Medical Center, Los Angeles, and a leading practitioner within the field of Lupus, and Prof. Cees GM Kallenberg, M.D., Ph.D. Prof. Department of Rheumatology and Clinical Immunology, University Medical Center Groningen who is a member of  the ‘European Organisation Committee’ for this forthcoming Lupus meeting. (Full biographies can be found in ‘Notes to Editors’).
Details of the presentation given by Dr. Slyvianne Muller will be provided by ImmuPharma following the conference.
Share this article